However, the COG AAML 1031 clinical trial, evaluating the addition of Sorafenib to standard chemotherapy as well as maintenance sorafenib following hematopoietic stem cell transplant (HSCT) for children with high allelic ratio FLT3-ITD+ AML showed improved CR rates as compared to historical controls following induction I (73% vs. 56%, p = 0.078) and following induction II (91% vs. 70%, p = 0.007). This evidence concerns the gene FLT3 and acute myeloid leukemia.